Comparative Pharmacology
Head-to-head clinical analysis: HIBISTAT versus PHISO SCRUB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIBISTAT versus PHISO SCRUB.
HIBISTAT vs PHISO-SCRUB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Active against susceptible gram-positive bacteria.
Phiso-Scrub is a topical antiseptic containing triclosan, which inhibits bacterial fatty acid synthesis by targeting enoyl-acyl carrier protein reductase (FabI), leading to disruption of cell membrane integrity and bacterial cell death.
1.5 mg/kg intravenously every 6 hours; maximum 120 mg per dose.
Topical application to affected area once daily; chlorhexidine gluconate 4% scrub, lather for 3-5 minutes, rinse thoroughly.
None Documented
None Documented
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Approximately 8-12 hours in patients with normal renal function (CrCl >90 mL/min). Half-life is significantly prolonged in renal impairment (up to 40 hours in ESRD).
Approximately 90% of absorbed dose excreted renally as unchanged drug; <5% in feces via biliary elimination.
Primarily renal excretion of unchanged drug (approximately 70-80% of absorbed dose). Biliary/fecal elimination accounts for the remainder (20-30%).
Category C
Category C
Antiseptic
Antiseptic